rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Scott Thomas Jackson

Director

Company insider

Files Form 4 as: Director, Spero Therapeutics; Director, MacroGenics; Director, Mural Oncology; Director, Crescent Biopharma; Chief Executive Officer, Celator Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
73
Buys
3
Sells
0
Bought
$58K
Sold
$0
Companies
5
Companies where not an officer
4
First trade
3 Jun 2013
Last trade
23 Jun 2026
Last filed
25 Jun 2026

Companies traded

Where they are an officer
Celator PharmaceuticalsDirector, Officer · last 12 Jul 20163 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
SPRO Spero TherapeuticsDirector · Biotechnology · last 23 Jun 20260 buys · 0 sells
MGNX MacroGenicsDirector · Biotechnology · last 19 May 20260 buys · 0 sells
Mural OncologyDirector · last 5 Dec 20250 buys · 0 sells
CBIO Crescent BiopharmaDirector · Biotechnology · last 1 May 20240 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Jun 2026filed 25 Jun 2026SPRO Spero TherapeuticsBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
23 Jun 2026filed 25 Jun 2026SPRO Spero Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
23 Jun 2026filed 25 Jun 2026SPRO Spero Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
23 Jun 2026filed 25 Jun 2026SPRO Spero TherapeuticsBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
19 May 2026filed 20 May 2026MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code A—3,750 at $0.00filing
19 May 2026filed 20 May 2026MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code A—3,750 at $0.00filing
19 May 2026filed 20 May 2026MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code A—22,000 at $0.00filing
19 May 2026filed 20 May 2026MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code A—22,000 at $0.00filing
18 May 2026filed 20 May 2026MGNX MacroGenicsBiotechnologySEC FORM 4 Code M—3,750filing
18 May 2026filed 20 May 2026MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code M—3,750 at $0.00filing
18 May 2026filed 20 May 2026MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code M—3,750 at $0.00filing
18 May 2026filed 20 May 2026MGNX MacroGenicsBiotechnologySEC FORM 4 Code M—3,750filing
5 Dec 2025filed 5 Dec 2025Mural Oncologyoption or derivativeSEC FORM 4 Code D—8,637filing
5 Dec 2025filed 5 Dec 2025Mural Oncologyoption or derivativeSEC FORM 4 Code D—8,462filing
5 Dec 2025filed 5 Dec 2025Mural Oncologyoption or derivativeSEC FORM 4 Code D—15,021filing
12 Jun 2025filed 16 Jun 2025SPRO Spero TherapeuticsBiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
11 Jun 2025filed 13 Jun 2025Mural Oncologyoption or derivativeSEC FORM 4 Code A—8,637 at $0.00filing
21 May 2025filed 22 May 2025MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code A—3,750 at $0.00filing
21 May 2025filed 22 May 2025MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code A—22,000 at $0.00filing
20 May 2025filed 22 May 2025MGNX MacroGenicsoption or derivative · BiotechnologySEC FORM 4 Code M—6,500 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed3

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.